The European Medicines Agency in October 2008 recommended the suspension of the sale of rimonabant as the risks seem to be greater than the benefits.
Evropska medicinska agencija je oktobra 2008 preporučila suspenziju prodaje rimonabanta jer je zaključeno da rizici nadmašuju korist.